ETF News

The broad Health Care sector of 14 funds rose 6.800% on the week. The catalyst came from Washington: the US Food and Drug Administration signalled on 17 June a more flexible approach to approving treatments for serious diseases, a shift that lifted UniQure shares by roughly 78% after the agency said it could refile its Huntington's disease gene therapy on three-year trial data. The week's contradiction is that the money did not follow the prices: the sector has shed cash across 2026 even as it climbed, and the strongest returns came from its smallest funds. Weekly gains ran from 5.269% to 8.561%.

A Record Year for Deals, and a Looser FDA

The structural force behind the sector is an M&A wave reshaping the wider industry and on track for its best year since 2019. Biopharma dealmaking totalled around US$106bn over 201 transactions in the first half of 2026 on PitchBook's count, a run rate that points to more than US$250bn for the full year, against US$209bn in 2025. Recent transactions, from Merck's purchase of Terns Pharmaceuticals and Novartis' move on Avidity Biosciences to Eli Lilly's deals for Ajax and Kelonia Therapeutics and Gilead's oncology buys of Arcellx and Tubulis, fit the pattern. The pull is structural: pharmaceutical companies face a wall of patent expiries on best-selling drugs and must refill their revenue lines, with the average deal size climbing to roughly US$527.3m this year from US$365m in 2025. The hunt for new science has increasingly turned to China, where buyers are taking ex-China rights to promising assets, and a divergence has opened between cash-rich franchises that attract willing partners and weaker names facing exclusivity losses that must originate their own deals. That impetus to acquire, set against an improving IPO window, has begun pulling generalist investors back towards the sector, even as the interest-rate environment has turned less supportive amid recent inflationary pressures and geopolitical conflict.

The week's spark, though, was regulatory. The FDA's willingness to entertain accelerated approvals for serious conditions marked a reversal from its earlier stance in the UniQure case, and the change has followed the exits of former Center for Biologics Evaluation and Research director Vinay Prasad and FDA commissioner Marty Makary. The benefit was not confined to one name. Atara Biotherapeutics and Replimune have seen approval pathways reopened after earlier cancer-treatment rejections, Moderna drew relatively favourable briefing documents ahead of an advisory committee meeting on its flu vaccine, and Biohaven's previously rejected neurological drug could find a more receptive reading under the new tone.

Small Funds Lead, Large Funds Leak

The rally was broad, but the year underneath it is a study in dispersion, and the two smallest funds in the cut have done the most. The BioTech & Genomics fund is up 31.005% year to date, and a NYSE Arca biotechnology vehicle is up 23.437%, against just 3.517% for the broad sector. The contrast carries into flows. The Health Care sector has seen net redemptions of about C$13.8m so far in 2026 despite its positive return, and the largest fund in the cut accounts for far more than that on its own. The sharpest counter-move sits in the year's weakest performer, which has pulled in the biggest year-to-date inflows of any Canadian fund here, a case of buyers accumulating an underperformer rather than chasing the leaders. The near-term catalysts are sector-specific rather than rate-driven: the Moderna advisory committee meeting on its flu vaccine is the next concrete regulatory test, the reopened pathways for Atara, Replimune, and Biohaven bear watching, and the deal pipeline shows little sign of slowing.

Canadian Healthcare and Biotech ETF Performance

At the aggregate level, the 14 Health Care sector funds hold approximately C$1.14bn in combined assets, returned 6.800% on the week and 3.517% year to date, and took in net weekly flows of about C$4.0m against year-to-date redemptions of roughly C$13.8m. The lone BioTech & Genomics theme fund holds about C$8.5m, returned 8.561% on the week and 31.005% year to date, with no net weekly flow and about C$1.09m of inflows year to date.

Genomics did the heavy lifting. The iShares Genomics Immunology and Healthcare Index ETF (XDNA), at roughly C$8.5m the smallest fund in the cut, led both the week and the year, rising 8.561% and 31.005% respectively, though it drew no fresh money this week.

Biotech ran a close second. The First Trust NYSE Arca Biotechnology ETF (FBT) rose 7.948% on the week and is up 23.437% year to date, and unlike the genomics fund it kept attracting money, taking in about C$0.87m on the week and C$2.98m year to date.

Among the broad names, a dividend fund led on returns and conviction. The Middlefield Healthcare Dividend ETF (MHCD) posted the strongest weekly gain of the broad sector at 8.044%, and backed it with inflows of about C$0.59m on the week and C$4.8m year to date, the healthiest flow profile of the larger funds.

Hedged US exposure rose without buyers. The BMO Equal Weight U.S. Health Care Index ETF, CAD Hedged (ZUH) returned 7.254% on the week and 4.189% year to date on zero net weekly flow, and has shed roughly C$13.5m over the year.

The largest fund carried the heaviest contrary flow. The iShares Global Healthcare Index ETF, CAD-Hedged (XHC), at about C$511.6m the biggest vehicle in the cut, rose 6.654% on the week but is up only 2.411% year to date and has seen the cut's largest redemptions, roughly C$57.9m, with no net flow this week.

The week's laggard drew the strongest demand. The TD Global Healthcare Leaders Index ETF (TDOC) returned the least in the cut, 5.269% on the week and 1.694% year to date, yet pulled in about C$0.996m this week and roughly C$30.95m year to date, the largest year-to-date inflow of any Canadian fund here and a clear case of buyers accumulating an underperformer.

Group Data

Fund Data

This article was written on June 29th, 2026. Please note this article is for information purposes only and does not in any way constitute investment advice. It is essential that you seek advice from a registered financial professional prior to making any investment decision.